Click here to view a write-up of the virtual event FROM BENCH TO BEDSIDE: GROWTH AND INNOVATION.
Tuesday, April 13, 2021
3:00 p.m. - 4:00 p.m. ET
The mouse model is a key platform for drug development. Join JAX to learn more about how the Laboratory is continuously innovating in the field of mouse model development. Leaders will share how JAX® Mice, Clinical and Research Services are developing new solutions in the preclinical path, helping scientists around the world drive their research forward, and, ultimately, helping patients across the globe.
For questions, contact Advancement Events at email@example.com.
Auro Nair, Ph.D., Executive Vice President of The Jackson Laboratory and President, JAX® Mice, Clinical and Research Services
Dr. Nair, executive vice president of The Jackson Laboratory and president, JAX® Mice, Clinical and Research Services, joined The Jackson Laboratory in 2007 as associate general manager of JAX® Mice and Services. The institution added clinical services to its offerings, and in 2011 Nair was named general manager of JAX® Clinical and Research Services, responsible for all clinical and scientific research services provided to internal researchers at The Jackson Laboratory and external researchers worldwide. In 2014 he was promoted to general manager, JAX® Mice, Clinical and Research Services with responsibility for all mouse production and operations added to his portfolio. Nair was promoted to president, JAX® Mice, Clinical and Research Services, in 2017 and was also promoted to executive vice president of The Jackson Laboratory in 2018.
James Keck, Ph.D, Senior Director, Innovation and Product Development
Keck’s expertise is in the therapeutic areas of oncology and inflammatory and metabolic diseases. During his career, he has led teams in pharmaceutical and biotechnology companies working in animal pharmacology, assay development, and drug discovery. At The Jackson Laboratory (JAX), Keck has overall responsibility for innovation and product development across multiple therapeutic areas, including the ongoing operational development of the immuno-oncology efficacy and cytokine release related toxicity platforms.